Simões EAF, et al. - Over the last 20 years, the REGAL (RSV Evidence – A Geographical Archive of the Literature) series has provided a comprehensive review of the published evidence in the field of respiratory syncytial virus (RSV) in Western countries. Researchers, in this seventh and final publication, reported on the past, present and future approaches to the prevention and treatment of RSV infection among infants and children. They recognized that palivizumab remained the only product licensed for RSV prophylaxis, and only available for high-risk infants. To significantly reduce the global healthcare impact of this common viral infection, several promising vaccines and monoclonal antibodies in various stages of clinical development were identified for the general population.